Challenges and recent advances in CAR-T cell therapy for solid tumors

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionized hematological cancer treatment.
• Significant hurdles impede the application of CAR-T therapy in solid tumors.

Purpose of the Study:

• This review consolidates current challenges and recent breakthrough strategies for CAR-T therapy in solid tumors.
• It aims to provide insights for advancing CAR-T research and clinical translation.

Main Methods:

• The review synthesizes information on obstacles like tumor antigen heterogeneity, immunosuppressive tumor microenvironment (TME), T-cell infiltration issues, and toxicities.
• It highlights innovative approaches including novel target discovery, advanced CAR designs, local delivery methods, and combination therapies.

Main Results:

• Novel targets such as Claudin 18.2 and B7-H3 are being investigated.
• Innovative CAR designs (logic-gated, armored CARs) and combination strategies (radiotherapy, checkpoint inhibitors, oncolytic viruses) show potential.
• Local delivery and in situ generation techniques are emerging solutions.

Conclusions:

• Overcoming solid tumor challenges requires innovative CAR-T strategies, novel targets, and advanced delivery systems.
• Multidisciplinary integration is crucial for developing intelligent, controllable next-generation CAR-T technologies for improved clinical outcomes.